Drugs / Carillizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04666090 | Nov 2020 → Dec 2022 overdue | esophageal squamous cell carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carillizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04666090 ↗ |
| Route | Intravenous | “Carillizumab 200mg, IV” NCT04666090 ↗ |